•1 min read•from TechCrunch
AI Biotech Enveda Accelerates Drug Development with $311M Investment
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Want to read more?
Check out the full article on the original site
Tagged with
#AI biotech
#nature-derived drugs
#clinical trials
#GLP-1s
#skin conditions
#weight loss
#drug development
#biotechnology
#artificial intelligence
#pharmaceuticals
#drug testing
#therapeutic
#medical
#healthcare
#GLP-1 receptor agonists
#clinical research
#investments
#venture capital
#drug discovery
#metabolic disorders